| 000 | 01844cam a2200349 a 4500 | ||
|---|---|---|---|
| 003 | EG-GiCUC | ||
| 005 | 20250223030742.0 | ||
| 008 | 130120s2012 ua d f m 000 0 eng d | ||
| 040 |
_aEG-GiCUC _beng _cEG-GiCUC |
||
| 041 | 0 | _aeng | |
| 049 | _aDeposite | ||
| 097 | _aPh.D | ||
| 099 | _aCai01.19.04.Ph.D.2012.Ah.T | ||
| 100 | 0 | _aAhmed Mohammad Mohi Eldin Ali | |
| 245 | 1 | 0 |
_aTreatment tailored therapy of diffuse large B-cell non hodgkin's lymphoma / _cAhmed Mohammad Mohi Eldin Ali ; Supervised Hussain Mostafa Khaled , Nadia Mahmoud Mokhtar , Foaad Mohammad AbuTaleb |
| 246 | 1 | 5 | _aتحديد طريقة علاج حالات أورام الغدد الليمفاوية غير الهودجكن ذات الخلايا الكبيرة حسب كل حالة مرضية |
| 260 |
_aCairo : _bAhmed Mohammad Mohi Eldin Ali , _c2012 |
||
| 300 |
_a175 P. : _bcharts ; _c25cm |
||
| 502 | _aThesis (Ph.D.) - Cairo University - National Cancer Institute - Department of Oncology-Medical | ||
| 520 | _aCD20-positive diffuse large B-cell lymphoma (DLBCL) accounts for approximately 40% of new cases of lymphoma. DLBCL is a heterogeneous disease that includes at least two prognostically important subtypes (i.e. germinal center B-cell like [GCB] and non-germinal center B-cell like [non-GCB]). These subtypes initially were characterized by gene expression profiling and subsequently were confirmed by immunostaining | ||
| 530 | _aIssued also as CD | ||
| 653 | 4 | _aCD20-positive diffuse large B-cell lymphoma | |
| 653 | 4 | _aR-CHOP | |
| 653 | 4 | _aRituximab | |
| 700 | 0 |
_aFoaad Mohammad Abutaleb , _eSupervisor |
|
| 700 | 0 |
_aHussain Mostafa Khaled , _eSupervisor |
|
| 700 | 0 |
_aNadia Mahmoud Mokhtar , _eSupervisor |
|
| 856 | _uhttp://172.23.153.220/th.pdf | ||
| 905 |
_aNazla _eRevisor |
||
| 905 |
_aSamia _eCataloger |
||
| 942 |
_2ddc _cTH |
||
| 999 |
_c41176 _d41176 |
||